Guideline

Cannabis-based medicinal products

Read time: 1 mins

Last updated:21st Mar 2021

Source: National Institute for Health and Care Excellence (NICE)

Cannabis-based medicinal products - National Institute for Health and Care Excellence (NICE)

This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.

March 2021: NICE has issued a clarification on recommendations for the use of unlicensed cannabis-based medicinal products for severe treatment-resistant epilepsy. This clarification has the same status as the guideline and should be read alongside it.

NICE has published technology appraisal guidance on cannabidiol with clobazam for treating seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.

Read full guideline